@article{d09643905f1c4266945e8b2a103e4184,
title = "The SYNTAX score on its way out or … towards artificial intelligence: part II",
author = "Serruys, \{Patrick W.\} and Ply Chichareon and Rodrigo Modolo and Leaman, \{David M.\} and Reiber, \{Johan H. C.\} and Emanuelsson, \{H. kan\} and \{di Mario\}, Carlo and Pijls, \{Nico H. J.\} and Marie-Ang{\`e}le Morel and Marco Valgimigli and Vasim Farooq and \{van Klaveren\}, David and Davide Capodanno and Daniele Andreini and Bourantas, \{Christos V.\} and Justin Davies and Banning, \{Adrian P.\} and Javier Escaned and Piek, \{Jan J.\} and Mauro Echavarr{\'i}a-Pinto and Taylor, \{Charles Anthony\} and Brian Thomsen and Carlos Collet and Giulio Pompilio and Bartorelli, \{Antonio L.\} and Ben Glocker and Ovidiu Dressler and Stone, \{Gregg W.\} and Yoshinobu Onuma",
note = "Funding Information: P.W. Serruys reports personal fees from Abbott Laboratories, AstraZeneca, Biotronik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Soci{\'e}t{\'e} Europa Digital \& Publishing, Stentys France, Svelte Medical Systems, Philips/ Volcano, St. Jude Medical, Qualimed, and Xeltis, outside the submitted work. P. Chichareon reports a research grant from Biosensors outside the submitted work. R. Modolo has received research grants from Biosensors outside the submitted work and from the Sao Paulo Research Foundation (FAPESP {\textendash} grant number 2017/22013-8). N. Pijls has received institutional research grants from Abbott, Hexacath and HeartFlow, is a consultant for Abbott, Opsens, and GE Healthcare, and possesses equity in Philips, HeartFlow, and ASML. M. Valgimigli reports grants and personal fees from Abbott, Terumo and AstraZeneca, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Alvimedica, Idorsia, Biosensors, CoreFlow, Vifor and Bristol-Myers Squibb, and grants from Medicure, outside the submitted work. J. Davies reports grants, personal fees and other from Philips Volcano, outside the submitted work; in addition, J. Davies has a patent iFR with royalties paid by Philips Volcano to Imperial College London. A. Banning is partially supported by the NIHR Oxford Biomedical Research Centre and reports grants from Boston Scientific and personal fees from Boston Scientific, Medtronic and Abbott Vascular, during the conduct of the study. J.J. Piek reports non-financial support from Abbott Vascular and personal fees and non-financial support from Philips/Volcano, outside the submitted work. B. Thomsen is an employee of GE Healthcare. B. Glocker reports grants from HeartFlow, and the European Commission, during the conduct of the study, personal fees from Kheiron Medical Technologies, Definiens, Axon Advisors, and GlaxoSmithKline, grants from UKRI, EPSRC, Innovate UK, and MRC/NIHR, outside the submitted work. C. Collet reports grants and personal fees from HeartFlow Inc, and personal fees from Philips and Abbott Vascular, outside the submitted work. G.W. Stone reports personal fees from Terumo, Amaranth, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, V-wave, Abiomed, Claret, Backbeat, Sirtex and MAIA Pharmaceuticals, personal fees and other from Ancora, Qool Therapeutics and SpectraWave, other from Cagent, Applied Therapeutics, Biostar family of funds, and MedFocus family of funds, outside the submitted work; Columbia University, his employer, receives royalties from Abbott for sales of the MitraClip. Y. Onuma reports being a member of the advisory board of Abbott Vascular. C. Taylor reports being a shareholder in and an employee of HeartFlow. The other authors have no conflicts of interest to declare. The Guest Editor is a consultant for Edwards Lifesciences.",
year = "2020",
doi = "10.4244/EIJ-D-19-00543B",
language = "English",
volume = "16",
pages = "60--75",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "1",
}
SDG 3 Good Health and Well-being